Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the additional excipients niacinamide and L-arginine. The improved pharmacological profile and greater early glucose-lowering action of faster aspart compared with IAsp suggests that faster aspart may be advantageous for people with diabetes using continuous subcutaneous insulin infusion (CSII). The recent onset 5 trial was the first to evaluate the efficacy and safety of an ultra-fast-acting insulin in CSII therapy in a large number of participants with type 1 diabetes (T1D). Noninferiority of faster aspart to IAsp in terms of change from baseline in HbA1c was 
severe or blood glucose-confirmed hypoglycaemia was not statistically significantly different between treatments, with an estimated rate ratio of 1.00 (95% CI, 0.85;
1.16). A numerical imbalance in severe hypoglycaemic episodes between faster aspart
and IAsp was seen in the treatment (21 vs 7) and the 4-week run-in periods (4 vs 0).
Experience from clinical practice indicates that all pump settings should be reviewed when initiating faster aspart with CSII, and that the use of continuous glucose monitoring or flash glucose monitoring, along with a good understanding of meal content and bolus type, may also facilitate optimal use. This review summarizes the available clinical evidence for faster aspart administered via CSII and highlights practical considerations based on clinical experience that may help healthcare providers and individuals with T1D successfully initiate and adjust faster aspart with CSII.
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| INTRODUCTION
Continuous subcutaneous insulin infusion (CSII) using an insulin pump is an increasingly popular treatment option for children and adults with type 1 diabetes (T1D). [1] [2] [3] In meta-analyses of randomized controlled trials, CSII is associated with improved glycaemic control and lower risk of severe hypoglycaemia compared with multiple daily injection (MDI) therapy. 4 CSII aims to mimic the physiological basal and prandial insulin profile, with basal infusion rates set to cover varying requirements during the night and between meals and useractivated bolus doses at mealtimes.
Most insulin pumps offer a range of pre-programmed bolus infusion types to provide coverage at mealtimes, including infusion of an entire bolus at once (standard bolus), infusion of small quantities over an extended period of time (delayed/extended bolus) or a combination of standard and delayed bolus (dual-/multi-wave). [5] [6] [7] Insulin pumps also have integrated bolus calculators that enable insulin dose calculation based on carbohydrate counting, personalized carbohydrate:insulin ratios, duration of insulin action and insulin sensitivity factors, and they allow insulin doses to be adjusted by one tenth of a unit or less, compared with one unit or half a unit with pen injectors.
Despite developments in insulin pump technology, there are a number of challenges in optimizing glycaemic control with CSII. These include optimization of basal and bolus infusion rates, selection of bolus type, time of meal bolus programming, variability of insulin action and type of insulin used. Calculation of appropriate insulin doses requires users to perform frequent blood glucose testing (selfmeasured blood glucose [SMBG]) at correct times or to use continuous glucose monitoring (CGM), 3, 8, 9 and to make accurate estimations of meal composition and carbohydrate content. 10, 11 Conventional insulin pumps involve an external infusion set to deliver insulin from the insulin reservoir in the pump housing into the subcutaneous tissue, while recently developed patch pumps deliver insulin via a very short internal infusion set. 12 Pump failure, and infusion set malfunctions or occlusions, can cause unexplained hyperglycaemia, ketosis and diabetic ketoacidosis. 13 The infusion site and the duration of infusion site usage can also impact the rate of insulin absorption and, consequently, the glucose-lowering action. decreased further to 7.44% in the faster aspart arm and to 7.35% in the IAsp arm. As expected with a treat-to-target design, noninferiority between treatments was confirmed with regard to change in HbA1c; however, the ETD was statistically significant in favour of IAsp (Table 1) . 38 In contrast, PPG increments at 30 minutes, 1 and 2 hours after a standardized meal test were statistically significantly reduced with faster aspart compared with IAsp. This was corroborated by lower post-prandial IG increments after 1 and 2 hours with faster aspart vs IAsp, measured during three approximately 2-week periods of blinded CGM (Table 1) . 38 The reasons for the discrepancy between the impact on HbA1c levels and PPG control are not fully clear. Participants did not change pump settings during the double-blinded trial period unless deemed necessary by an investigator; thus, pump parameters were optimized for RAIAs rather than faster aspart use. Nocturnal and pre-meal levels of IG were slightly higher in participants receiving faster aspart compared with those receiving IAsp. Elevated nocturnal IG in the faster aspart treatment arm may have been the result of a suboptimal bolus type (ie, dual-/multi-wave vs standard bolus) for the composition of the evening meal (eg, fat content), a lack of basal insulin compensation because of the shorter bolus insulin action, or suboptimal basal insulin rates during the night.
| Continuous subcutaneous insulin infusion setting
The rate of overall severe or BG-confirmed hypoglycaemia was not different between treatments; however, consistent with its faster pharmacokinetic/pharmacodynamic (PK/PD) profile, the rate of the small proportion of episodes that occurred during the first hour after a meal was higher for faster aspart vs IAsp (Table 1) . While the trial was not powered to assess differences in severe hypoglycaemia, the number of episodes was numerically higher for faster aspart vs IAsp.
Eleven participants treated with faster aspart reported 21 episodes and five participants treated with IAsp reported seven episodes. This imbalance was also observed during the run-in period, with four episodes reported by three participants who were later randomized to faster aspart. Unlike many clinical trials of CSII, it is important to note that individuals with hypoglycaemia unawareness or with preceding severe hypoglycaemia were not excluded from this trial, and there was no stratification for these parameters. A similar rate of infusion set changes (routine and non-routine) was reported with both treatments, although a numerically higher number of infusion-site reactions, a cited reason for non-routine changes, was reported with faster aspart vs IAsp (Table 1 ). a P values from a two-sided test for treatment difference evaluated at the 5% level.
| Closed-loop automated insulin delivery systems
b P values from a one-sided test for non-inferiority and superiority evaluated at the 2.5% level.
lacking. Herein, we highlight important considerations that may aid healthcare providers (HCPs) and individuals with diabetes in successfully initiating and adjusting faster aspart with CSII. A number of these considerations will probably also apply to other ultra-fast-acting insulins currently in development.
As in the onset 5 trial, a 1:1 unit dose conversion is recommended when switching to faster aspart. However, while pump settings may have been ideal for the previously used insulin, given the difference in pharmacology, a review of and guided change in all pump settings should be expected over the weeks and months following the switch. Differences in bolus delivery between different insulin pumps should also be taken into consideration, as these can affect the pharmacological characteristics of mealtime insulin 44 and may also influence the "insulin on board" or active insulin estimation, that is, the residual glucose-lowering activity from prior boluses, and therefore, the correction bolus dosing.
Because of the accelerated absorption kinetics of faster aspart, bolus dosing will need to be addressed to reduce the risk of early post-prandial hypoglycaemia or late post-prandial hyperglycaemia.
Early post-prandial hypoglycaemia is uncommon, but it may become an issue after unexpectedly delayed meals or meals with a high fat content, errors in carbohydrate counting, or in patients with gastroparesis. Data suggest that administration of a pre-prandial bolus of ultra-rapid-acting insulin 15 minutes before a meal, compared with immediately before, can improve post-prandial hyperglycaemia. 45 While this was not examined in the onset 5 trial, clinical experience suggests that pre-meal bolus dosing can be beneficial for pump users with faster aspart, especially when consuming food with a high glycaemic index. Adjustments to the basal insulin dose, potentially using a basal rate test, will also need to be taken into consideration for optimal use of faster aspart, 46 although HCPs should be aware that some pump users will not be accustomed to changing basal rate parameters without support from their treatment team. The occurrence of a burning sensation around the infusion site has been reported in some individuals using faster aspart in clinical practice. Some users also report the necessity of changing their infusion set more frequently after switching to faster aspart to avoid hyperglycaemia, and others have found that correction doses are not as effective as expected. There are likely to be other, currently unknown, factors involved in determining the success of treatment with faster aspart using CSII, and HCPs may find that improvements in glycaemic control are seen in some users, but not necessarily all. Healthcare plc, for medical writing and editorial assistance in the
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